Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Methotrexate/6-mercaptopu… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.

Artikel i vetenskaplig tidskrift
Författare Kjeld Schmiegelow
Ibrahim Al-Modhwahi
Mette Klarskov Andersen
Mikael Behrendtz
Erik Forestier
Henrik Hasle
Mats Heyman
Jon Kristinsson
Jacob Nersting
Randi Nygaard
Anne Louise Svendsen
Kim Vettenranta
Richard Weinshilboum
Berit Kriström
Lotta Mellander
Publicerad i Blood
Volym 113
Nummer/häfte 24
Sidor 6077-84
ISSN 1528-0020
Publiceringsår 2009
Publicerad vid Institutionen för kliniska vetenskaper, Avdelningen för pediatrik
Sidor 6077-84
Språk en
Länkar dx.doi.org/10.1182/blood-2008-11-18...
Ämnesord 6-Mercaptopurine, administration & dosage, adverse effects, Administration, Oral, Adolescent, Antineoplastic Combined Chemotherapy Protocols, adverse effects, Child, Child, Preschool, Combined Modality Therapy, Cranial Irradiation, Female, Follow-Up Studies, Humans, Immunoenzyme Techniques, Infant, Karyotyping, Male, Methotrexate, administration & dosage, adverse effects, Methyltransferases, metabolism, Neoplasms, Second Primary, chemically induced, diagnosis, metabolism, Precursor Cell Lymphoblastic Leukemia-Lymphoma, drug therapy, pathology, radiotherapy, Prognosis, Remission Induction, Risk Factors, Stem Cell Transplantation, Survival Rate, Treatment Outcome
Ämneskategorier Pediatrik

Sammanfattning

Among 1614 children with acute lymphoblastic leukemia (ALL) treated with the Nordic Society for Paediatric Haematology and Oncology (NOPHO) ALL-92 protocol, 20 patients developed a second malignant neoplasm (SMN) with a cumulative risk of 1.6% at 12 years from the diagnosis of ALL. Nine of the 16 acute myeloid leukemias or myelodysplastic syndromes had monosomy 7 (n = 7) or 7q deletions (n = 2). In Cox multivariate analysis, longer duration of oral 6-mercaptopurine (6MP)/methotrexate (MTX) maintenance therapy (P = .02; longest for standard-risk patients) and presence of high hyperdiploidy (P = .07) were related to increased risk of SMN. Thiopurine methyltransferase (TPMT) methylates 6MP and its metabolites, and thus reduces cellular levels of cytotoxic 6-thioguanine nucleotides. Of 524 patients who had erythrocyte TPMT activity measured, the median TPMT activity in 9 patients developing an SMN was significantly lower than in the 515 that did not develop an SMN (median, 12.1 vs 18.1 IU/mL; P = .02). Among 427 TPMT wild-type patients for whom the 6MP dose was registered, those who developed SMN received higher average 6MP doses than the remaining patients (69.7 vs 60.4 mg/m2; P = .03). This study indicates that the duration and intensity of 6MP/MTX maintenance therapy of childhood ALL may influence the risk of SMNs in childhood ALL.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?